1-ethyl-ethanediyldiamine; dihydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-ethyl-ethanediyldiamine; dihydrochloride
• 英文别名: 1-Aethyl-aethandiyldiamin; Dihydrochlorid；Butane-1,2-diamine hydrochloride；butane-1,2-diamine;hydrochloride
• 化学式: C₄H₁₂N₂*2ClH
• 分子量: 161.075
• InChiKey: WJGOVGSPFUEPQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethyl-ethanediyldiamine; dihydrochloride 、 酮基丙二酸二乙酯 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 21.67h， 以25%的产率得到ethyl 5-ethyl-3-hydroxypyrazine-2-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of hedgehog signaling inhibitor with novel core system

  摘要：

  As we previously reported, N-methylpyrrolo[3,2-c] pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.036

文献信息

• Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
  申请人：Ohashi Tomohiro

  公开号：US08486965B2

  公开（公告）日：2013-07-16

  The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

  本发明提供了一种具有强Smoo抑制活性的融合杂环衍生物及其使用。具体而言，本发明涉及一种由式表示的化合物，其中每个符号如规范中定义，或其盐，以及含有该化合物或其前药的药物，其为Smoo抑制剂或癌症预防或治疗剂。
• FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2471789B9

  公开（公告）日：2015-03-25
• Synthesis and evaluation of hedgehog signaling inhibitor with novel core system
  作者：Tomohiro Ohashi、Yuta Tanaka、Zenyu Shiokawa、Hiroshi Banno、Toshio Tanaka、Sachio Shibata、Yoshihiko Satoh、Hiroko Yamakawa、Yukiko Yamamoto、Harumi Hattori、Shigeru Kondo、Maki Miyamoto、Hideaki Tojo、Atsuo Baba、Satoshi Sasaki

  DOI：10.1016/j.bmc.2015.05.036

  日期：2015.8

  As we previously reported, N-methylpyrrolo[3,2-c] pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages. (C) 2015 Elsevier Ltd. All rights reserved.